# Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

> **NCT06114329** · PHASE2 · RECRUITING · sponsor: **AceLink Therapeutics, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** AL01211

## Key facts

- **NCT ID:** NCT06114329
- **Lead sponsor:** AceLink Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2024-12
- **Final completion:** 2026-06
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06114329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06114329, "Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06114329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*